
Central African Republic ALMA Quarterly Report Quarter Three, 2023




Scorecard for Accountability and Action



Commodities Financed		
LLIN financing 2023 projection (% of need)		100
Public sector RDT financing 2023 projection (% of need)		100
Public sector ACT financing 2023 projection (% of need)		100
Policy		
Signed, ratified and deposited the AMA instrument at the		
Malaria activities targeting refugees in Malaria Strategic Plan		
Malaria activities targeting IDPs in Malaria Strategic Plan		
Zero Malaria Starts With Me Launched		
End Malaria Council and Fund Launched		
Resistance Monitoring, Implementation and Impact		
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		4
Insecticide resistance monitored since 2015 and data reported to WHO		
National Insecticide Resistance Monitoring and Management Plan		
RDTs in stock (>6 months stock)		
ACTs in stock (>6 months stock)		
LLIN/IRS campaign on track		
Operational LLIN/IRS coverage (% of at risk population)		100
On track to reduce case incidence by ≥40% by 2021 (vs 2015)		
On track to reduce case mortality by ≥40% by 2021 (vs 2015)		
Tracer Indicators for Maternal and Child Health, NTDs ar	nd C	ovid 19
Scale of Implementation of ICCM		
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021)		43
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2022)		36
Vitamin A Coverage 2022 (2 doses)		
DPT3 coverage 2022 (vaccination among 0-11 month olds)		42

There is intense malaria transmission all year round in the Central African Republic and the entire population of the country is at high risk. The annual reported number of malaria cases in 2021 was 2,223,562 with 2,412 deaths.

Key



Central African Republic ALMA Quarterly Report, Quarter Three, 2023



Malaria

Progress

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard Central African Republic has procured sufficient LLINs to achieve universal operational coverage of the targeted at-risk population. Central African Republic has recently submitted insecticide resistance monitoring data to WHO and has carried out drug resistance testing since 2018 and has reported the results to WHO. The ACTs, RDTs and LLINs needed for 2023 are fully financed. The national strategic plan includes activities targeting IDPs.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, the country should consider establishing an End Malaria Council and Fund to enhance domestic resource mobilization and multi-sectoral action. The country has recently rolled out their malaria scorecard for accountability and action.

Impact

The annual reported number of malaria cases in 2021 was 2,223,562 with 2,412 deaths.

Key Challenges

- Limited access to some at-risk populations is hampering coverage of malaria control interventions.
- Limited resources to further scale-up interventions.

Previous Key Recommended Actions

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Policy	Sign, ratify and deposit the AMA instrument at the AUC	Q1 2023		No progress reported

Central African Republic has responded positively to the recommended actions on drug resistance testing and on the development and implementation of a national insecticide resistance monitoring and management plan and reporting on the status of insecticide resistance monitoring to WHO.

RMNCAH and NTDs

Progress in addressing Neglected Tropical Diseases (NTDs) in Central African Republic is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, onchocerciasis, schistosomiasis, soil transmitted helminths and trachoma. Preventive chemotherapy coverage in Central African Republic is very low for schistosomiasis (16%), low for soil transmitted helminths (43%), onchocerciasis (61%) and for trachoma (47%). It is good for lymphatic filariasis (77%). Overall, the NTD preventive chemotherapy coverage index for Central African Republic in 2021 is 43 and this represents a very substantial increase compared with the 2020 index value (0).

Previous Key Recommended Actions

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
NTDs	Work to increase the preventive chemotherapy coverage for schistosomiasis, soil transmitted helminthiasis, Onchocerciasis and for trachoma and reach WHO targets. Prioritise the key necessary catch-up activities as well as conducting stock reconciliation following a national and subnational physical inventory count tracking of leftover stocks at district level and retrieving all expired drugs after MDA for incineration and accountability	Q4 2023		During Q2 and Q3 2023, the country has carried out MDA for Onchocerciasis, Schistosomiasis, Soil Transmitted Helminths and Lymphatic Filariasis. Due to security issues and limited funds, the activity is still ongoing, to be completed by the end of the year. The country is scaling down MDA for trachoma and surveillance activities are ongoing. Other NTD routine activities are being conducted.

The country has responded to the RMNCAH recommended actions addressing the lack of data for vitamin A and continues to track progress as this action is implemented.

